ANIP
ANI Pharmaceuticals, Inc.
ANIP has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ANIP overall, supported by stronger fundamentals and stronger modeled upside.
ANIP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Unavailable | |
| Strong |
ANIP's profitability and balance sheet are currently healthy, and its revenue is stable. There isn't enough data to rate its cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANIP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.5x | $71.06 | — |
| Current | 14x | $71.06 | — |
| Cheap | 21x | $103 | +45% |
| Fair | 46x | $228 | +221% |
| Expensive | 81x | $406 | +471% |
Historical ranges are pointers, not guarantees.
ANIP's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 7.5x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ANIP in the historical PE scenario, which offers more potential upside but is not a forecast.
ANIP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for ANIP, but weaker profitability.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ANIP on the outlook, with more favorable profitability expectations.
ANIP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.52 | +91% |
| Q3 2026 | $4.98 | +188% |
| Q2 2026 | $4.60 | +$5.27 |
| Q1 2026 | $3.91 | +$5.08 |
| Q4 2025 | $3.32 | +$4.36 |
| Q3 2025 | $1.73 | +$2.27 |
| Q2 2025 | -$0.67 | -157% |
| Q1 2025 | -$1.17 | -173% |
| Q4 2024 | -$1.04 | -222% |
ANIP has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ANIP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $148.3M | +13% |
| Q2 2024 | $138M | +18% |
| Q1 2024 | $137.4M | +29% |
| Q4 2023 | $131.7M | +40% |
| Q3 2023 | $131.8M | +57% |
| Q2 2023 | $116.5M | +58% |
| Q1 2023 | $106.8M | +66% |
| Q4 2022 | $94.2M | +55% |
OSCR has the stronger quarterly revenue trend. Revenue is up 13% for ANIP versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -14% | -27 points |
| Q2 2024 | 3.7% | -6.9 points |
| Q1 2024 | 15% | +5.5 points |
| Q4 2023 | 5.1% | +3.2 points |
| Q3 2023 | 14% | +20 points |
| Q2 2023 | 11% | +28 points |
| Q1 2023 | 9.3% | +39 points |
| Q4 2022 | 1.9% | +41 points |
ANIP's operating margin was −14% last quarter, down 27 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ANIP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $70.3M | +85% |
| Q2 2026 | $53.6M | -25% |
| Q1 2026 | $52.3M | +61% |
| Q4 2025 | $29.1M | +116% |
| Q3 2025 | $38M | +395% |
| Q2 2025 | $71.8M | +454% |
| Q1 2025 | $32.5M | +138% |
| Q4 2024 | $13.5M | -68% |
ANIP generated $205M in free cash flow over the past year, up 32% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ANIP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -240K shares |
| 1 year | +2.8% | +582K shares |
| 3 years | +13% | +2.5M shares |
| 5 years | +79% | +9.6M shares |
| Available history | +80% | +9.6M shares |
ANIP has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.6M |
| Q2 2026 | $813,000 |
| Q1 2026 | $19.8M |
| Q4 2025 | $611,000 |
| Q3 2025 | $1M |
| Q2 2025 | $551,000 |
| Q1 2025 | $10M |
| Q4 2024 | $318,000 |
ANIP spent $35M buying back its own shares over the past year, up 192% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ANIP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 2.5x | Moderate |
ANIP has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ANIP on leverage, with a lower net debt burden relative to earnings.
ANIP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 17.1 | Oversold |
ANIP's weekly RSI is 44 (neutral) and its Stochastic is 17 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ANIP PE vs Healthcare Sector
| Metric | ANIP | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 1 | 29 | 28 pts below |
ANIP is trading at 14x earnings, a 45% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ANIP on valuation relative to its sector.
ANIP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.9 | 1.2% below |
| 20 week MA | $75.0 | 5.3% below |
| 50 week MA | $77.5 | 8.3% below |
| 100 week MA | $74.7 | 4.9% below |
| 200 week MA | $65.2 | 8.9% above |
ANIP has fallen below most of its moving averages, though it's still 8.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ANIP on trend strength, trading above more of its moving averages.
ANIP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.3 | $28.0 | -54% |
| 2021 | $28.0 | $50.9 | +82% |
| 2022 | $50.9 | $39.5 | -22% |
| 2023 | $39.5 | $55.1 | +40% |
| 2024 | $55.1 | $54.4 | -1.3% |
| 2025 | $54.4 | $82.4 | +51% |
| 2026 YTD | $82.4 | $71.1 | -14% |
ANIP has finished lower in three of the last six years. It's down 14% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ANIP on returns for 2026, with the stronger performance.